SQZ vs. SGLY, CISS, PSIG, USDP, MOND, AIRTP, ATCOL, BLDEW, RA, and IMPPP
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include Singularity Future Technology (SGLY), C3is (CISS), PSI Group (PSIG), USD Partners (USDP), Mondee (MOND), Air T (AIRTP), Atlas (ATCOL), Blade Air Mobility (BLDEW), Brookfield Real Assets Income Fund (RA), and Imperial Petroleum (IMPPP). These companies are all part of the "transportation" industry.
SQZ Biotechnologies vs.
Singularity Future Technology (NASDAQ:SGLY) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Singularity Future Technology has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500.
Singularity Future Technology has higher earnings, but lower revenue than SQZ Biotechnologies. Singularity Future Technology is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Singularity Future Technology had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Singularity Future Technology and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.00 beat Singularity Future Technology's score of -1.00 indicating that SQZ Biotechnologies is being referred to more favorably in the news media.
SQZ Biotechnologies received 10 more outperform votes than Singularity Future Technology when rated by MarketBeat users.
4.1% of Singularity Future Technology shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 10.2% of Singularity Future Technology shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Singularity Future Technology has a net margin of -132.89% compared to SQZ Biotechnologies' net margin of -369.96%. Singularity Future Technology's return on equity of -25.97% beat SQZ Biotechnologies' return on equity.
Summary
Singularity Future Technology and SQZ Biotechnologies tied by winning 7 of the 14 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
This page (NYSE:SQZ) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy SQZ Stock Free SQZ Stock Alerts